Trials / Completed
CompletedNCT01876719
AR08 for Treatment of ADHD in Children
A Randomized, Double-Blind, Placebo-Controlled, Forced Titration, Proof-of-Concept Study of AR08 in the Treatment of Attention Deficit Hyperactivity Disorder in Children (Ages 6 - 17)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Arbor Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio. One-hundred twenty (120) patients are planned to be randomized. Each patient will receive AR08 (0.5, 1, or 2 mg per day) or matching placebo for seven (7) weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AR08 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2014-10-01
- Completion
- 2015-02-01
- First posted
- 2013-06-13
- Last updated
- 2015-12-09
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01876719. Inclusion in this directory is not an endorsement.